VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placebo Reduction in lung fibrosis from VYN201 ...
first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...
GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and ...
MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today ...
On Thursday, MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) announced the formulation of Ketamir-2 as a topical treatment for localized neuropathic and inflammatory pain. The advancement expands the ...
BERWYN, Pa.--(BUSINESS WIRE)-- Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as ...
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback